Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
← catalyst calendarNCT07181161 · readout in 883 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
177estimated
Sites
52
Countries
Brazil, China, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-01 | actual | When the study began enrolling |
| Primary completion | 2029-01-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-01-18 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Prostate Cancer
Interventions
- Drug: AZD0516
- Drug: AZD9574
Primary outcomes
what the primary-completion date above is the date OFModule 1 and 2: Parts A and B: Number of participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Event of Special Interests (AESIs)
measured From Day 1 up to approximately 3 years
Module 1 and 2: Part A: Number of participants with Dose Limiting Toxicities (DLTs)
measured From Day 1 up to end of DLT period (approximately 21 days)
Module 1: Parts B and C and Module 2: Part B: Percentage of participants with Prostate-Specific Antigen (PSA) 50 response rate
measured Up to approximately 2 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed